223 related articles for article (PubMed ID: 32397113)
41. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
42. "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Rasmussen B; Göhring G; Bernard E; Nilsson L; Tobiasson M; Jädersten M; Garelius H; Dybedal I; Grønbaek K; Ejerblad E; Lorenz F; Flogegård M; Marcher CW; Öster Fernström A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Nørgaard JM; Saft L; Möllgård L; Hellström-Lindberg E
Leukemia; 2022 May; 36(5):1436-1439. PubMed ID: 35277655
[No Abstract] [Full Text] [Related]
43. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
44. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
[TBL] [Abstract][Full Text] [Related]
45. Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Santini V; Fenaux P; Giagounidis A; Platzbecker U; List AF; Haferlach T; Zhong J; Wu C; Mavrommatis K; Beach CL; MacBeth KJ; Almeida A
Leukemia; 2021 Mar; 35(3):897-900. PubMed ID: 32661294
[No Abstract] [Full Text] [Related]
46. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
47. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
48. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Chesnais V; Renneville A; Toma A; Lambert J; Passet M; Dumont F; Chevret S; Lejeune J; Raimbault A; Stamatoullas A; Rose C; Beyne-Rauzy O; Delaunay J; Solary E; Fenaux P; Dreyfus F; Preudhomme C; Kosmider O; Fontenay M;
Blood; 2016 Feb; 127(6):749-60. PubMed ID: 26626993
[TBL] [Abstract][Full Text] [Related]
49. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
[TBL] [Abstract][Full Text] [Related]
50. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
51. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
52. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Komrokji RS; List AF
Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
[TBL] [Abstract][Full Text] [Related]
53. Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.
Martinez-Høyer S; Deng Y; Parker J; Jiang J; Mo A; Docking TR; Gharaee N; Li J; Umlandt P; Fuller M; Jädersten M; Kulasekararaj A; Malcovati L; List AF; Hellström-Lindberg E; Platzbecker U; Karsan A
Nat Cell Biol; 2020 May; 22(5):526-533. PubMed ID: 32251398
[TBL] [Abstract][Full Text] [Related]
54. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
55. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
56. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Komrokji RS; Zeidan AM
J Blood Med; 2015; 6():1-16. PubMed ID: 25565910
[TBL] [Abstract][Full Text] [Related]
57. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).
Belickova M; Cermak J; Dostalova Merkerova M; Vesela J; Krejcik Z; Cechova E; Zemanova Z; Michalova K; Votavova H; Caniga M; Neuwirtova R; Jonasova A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):375-83. PubMed ID: 22608605
[TBL] [Abstract][Full Text] [Related]
58. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Komrokji RS; Al Ali NH; Padron E; Cogle C; Tinsley S; Sallman D; Lancet JE; Lis AF
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):251-254. PubMed ID: 30852241
[TBL] [Abstract][Full Text] [Related]
59. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
60. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.
McGraw KL; Zhang LM; Rollison DE; Basiorka AA; Fulp W; Rawal B; Jerez A; Billingsley DL; Lin HY; Kurtin SE; Yoder S; Zhang Y; Guinta K; Mallo M; Solé F; Calasanz MJ; Cervera J; Such E; González T; Nevill TJ; Haferlach T; Smith AE; Kulasekararaj A; Mufti G; Karsan A; Maciejewski JP; Sokol L; Epling-Burnette PK; Wei S; List AF
Blood Cancer J; 2015 Mar; 5(3):e291. PubMed ID: 25768405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
